Physician profile
Sara Phillips
NPI 1710419973
$5,501.32
in general payments reported to CMS, 2019-2025
17 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.42 · 2022: $651 · 2023: $746 · 2024: $1,289 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,625 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,625.48 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,038.49 | 2021-2025 | |
| Janssen Biotech, INC. | $970.47 | 2022-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $423.17 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $259.98 | 2024-2025 | |
| Organon LLC | $255.83 | 2025 | |
| Galderma Laboratories, L.P. | $231.94 | 2024-2025 | Nemluvio, Aklief |
| Ucb, INC. | $218.39 | 2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $213.52 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $202.91 | 2021-2025 | |
| Incyte Corporation | $165.97 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $104.45 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.17 | 2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $93.99 | 2024-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $88.23 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $63.56 | 2024-2025 | Ycanth |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $42.76 | 2025 | Zelsuvmi |
| Novartis Pharmaceuticals Corporation | $29.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.